RxDoctor Payments Data

Steven Cimerberg, DO

Adult Medicine · North Lauderdale, FLNPI 1760667968

Payments from drug & device makers

$256in general payments, 2019–2025

Across 9 payments — averaging $28.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$139
  • Genentech USA, Inc.$36
  • Lilly USA, LLC$23
  • Medicure Pharma Inc.$18
  • AbbVie$14
  • Johnson & Johnson$14
  • plus $13 from 1 others

What the payments were for

  • Speaking & faculty fees$187%
  • Food & beverage$23993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$256 in reported general payments places this provider in the 40th percentile of 195 adult medicine providers in Florida.

See all adult medicine providers in Florida

Medicare billing

Part B allowed, 2024
$108,620
Medicare patients
369
Services billed
1,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$26,646
XareltoRivaroxaban11$16,145
OzempicSemaglutide11$12,311
SynthroidLevothyroxine Sodium23$2,264
Atorvastatin Calcium177$1,689
Losartan Potassium103$1,341
Rosuvastatin Calcium119$1,297
Amlodipine Besylate159$1,179
Levothyroxine Sodium135$1,178
Escitalopram Oxalate56$961
Gabapentin44$918
Pantoprazole Sodium53$849
Metoprolol Succinate46$784
ClopidogrelClopidogrel Bisulfate29$751
Ezetimibe23$744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$14$16,14511 claims
Novo NordiskOzempic$139$12,31111 claims
AbbVieSynthroid$14$2,26423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 195 adult medicine providers in Florida.

Other adult medicine in North Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →